Amarin Corporation to Announce Quarterly Earnings on March 12, Analysts Predict EPS of $0.06

Summary

Amarin (NASDAQ: AMRN) is set to release its quarterly earnings report on March 12 before market opens. Analysts are predicting an EPS of ($0.06) and revenue of $32.37 million. The stock opened at $0.51 with a market cap of $209.48 million. Recently, stocknews.com downgraded Amarin’s rating from ‘hold’ to ‘sell’. The company focuses on cardiovascular disease treatments, particularly Vascepa to lower triglyceride levels. Market Beat

Impact Analysis

1. Business Overview Analysis:

• Core Business Model: Amarin specializes in cardiovascular treatments, with its flagship product being Vascepa, which is used to lower triglyceride levels.
• Market Position: The company has a niche focus in the pharmaceutical industry, specifically targeting the cardiovascular segment.
• Recent Events: The downgrade by stocknews.com to ‘sell’ could indicate concerns about the company’s prospects or recent performance. This may impact investor sentiment negatively.

2. Financial Statement Analysis:

• Income Statement: Analysts predict an EPS of ($0.06), which indicates a loss per share, suggesting the company may be struggling to turn a profit. The revenue estimate stands at $32.37 million.
• Balance Sheet & Cash Flow: No specific balance sheet or cash flow information is provided in the event summary. However, the low stock price and market cap might suggest potential liquidity or solvency concerns.
• Financial Ratios: Without detailed financial data, exact calculations for ratios like ROE, ROA, etc., cannot be determined. The market’s downgrade and projected negative EPS signal potential profitability challenges.

3. Valuation Assessment:

• Given the downgrade and the low stock price, Amarin’s current market valuation may be under pressure. Comparison with industry peers would be needed to assess if the stock is undervalued or overvalued.

4. Opportunity/Risk Assessment:

• Risks include the downgrade to ‘sell’ and potential ongoing losses, which could affect stock performance.
• Opportunities could involve strategic moves to strengthen its market position or expand its product line to improve financial health.